AzTrials
AzTrials

Smoking Cessation; Tobacco DependenceNCT07030387

Evaluation of the Effectiveness of a Very Brief Smoking Cessation Intervention in Family Health Centers

A study testing Smoking cessation counselling group in people with Smoking Cessation; Tobacco Dependence, run by Aydin Adnan Menderes University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In Turkey, the prevalence of tobacco use among individuals was 31.4% in 2019. The WHO recommends brief and very brief interventions to increase tobacco cessation rates and medical support. In developing countries, these brief interventions are being integrated into primary care. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Smoking Cessation; Tobacco Dependence
What is being tested?
Smoking cessation counselling group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
330 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jun 2023to 31 Mar 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All smokers aged 18 and above who visited selected Family Health Centers

Who cannot join

  • Smokers experiencing cooperation and communication issues
  • Smokers who have received support for a smoking cessation attempt within the last month

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Assigned Family Health Centers within Aydin Province

    Efeler, Aydın, 09100

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of the Effectiveness of a Very Brief Smoking Cessation Intervention in Family Health Centers: A Pragmatic Randomized Controlled Trial

In Turkey, the prevalence of tobacco use among individuals was 31.4% in 2019. The WHO recommends brief and very brief interventions to increase tobacco cessation rates and medical support. In developing countries, these brief interventions are being integrated into primary care. The aim of this study is to evaluate the effectiveness of very brief interventions at different family health centers in Aydın province.

A pragmatic randomized controlled trial was conducted with 170 patients in intervention group and 161 in control group across 14 family health centers in Aydın province from June 2023 to December 2023. Physicians that recurited for intervention received one hour of online training before applying very brief smoking cessation interventions to their patients. Data collection included a baseline assessment of sociodemographic characteristics, smoking status, and medical history. At the three-month follow-up, participants' cessation status and motivations were assessed via phone call interviews. Intention to Treat approach was utilized. Secondary outcomes included the objective and subjective frequency of smoking, as well as treatment and support received.

Read the detailed description

INTRODUCTION:

Tobacco use is among the leading causes of preventable mortality. One in ten deaths is related to tobacco use worldwide. Expected lifespan of smokers is ten years shorter than non-smokers and half of them lose around 20 Quality-Adjusted Life Years (QALYs) due to tobacco related diseases before death.

The motto "Offer help to quit tobacco use" has the worst progression within MPOWER strategies of WHO. Smoking cessation services are especially inadequate in developing countries, and even when offered free of charge, their utilisation rates remain low.

On the other hand, brief physician advice enhances the quitting rates of smokers. WHO recommends brief clinical interventions to enhance tobacco cessation rates. Former studies show that these interventions increase the cessation rates. A meta-analysis specifically examining brief interventions integrated into primary care setting has found that they effectively improve smoking cessation rates. Therefore, authors suggest that behavioural healthcare services should be integrated into primary care to promote tobacco cessation intervention.

However, these interventions, which WHO defines as "brief", last 3-10 minutes and are difficult to implement in busy clinical practice settings where the time is allocated to a patient is limited. Lack of time and poor education are the main barriers to physicians using these interventions efficiently.

To increase physicians' adherence, very brief interventions (30-60 seconds) are also recommended. AAR (Ask-Advice-Refer) brief intervention, which has been developed based on 5A approach, prioritises increasing awareness, advice and referral. AAC (Ask-Advice-Connect) approach which aims to increase the uptake of referral smokers to smoking cessation counseling services is also recommended. AWARD (Ask-Warn-Advice-Refer-Do it again) and WAR (Warn-Advice-Refer) models emphasise the warning that "one in every two smokers dies because of smoking". These very brief interventions do not focus on smokers' motivation to quit. The 3A-OR very brief intervention which is conducted in family health centers consists of the steps "Ask-Assess-Advice-Offer-Record". This intervention primarily evaluates smokers' motivation of quit and can be tailored according to smoker's motivation level.

Studies evaluating the effectiveness and feasibility of very brief interventions are limited, with outcomes from only three recent studies to date. Nevertheless, these studies are mostly explanatory RCT's and have been conducted in hospitals.

In Türkiye, RCTs on this topic appear highly limited. The trial of the effectiveness of an intervention emphasising "Harm effects of Second hand tobbacco exposure on their children" to smoker mothers has been conducted in tertiary care hospital in 2006. Implementation and effectiveness of very brief smoking cessation interventions in primary care settings are unknown.

This study aims to evaluate effectiveness of 3A-OR very brief smoking cessation intervention in improving motivation levels and increasing quit rates of smokers in routine primary care practices.

METHODS:

Study design:

This paralelled multi-site pragmatic randomized controlled trial recruited smokers from 17 family health centers in primary care in the city of Aydın, Türkiye, from June 2023 to December 2023.

Ethical approval was granted by Ethics Committee of Adnan Menderes University Medical School. Written informed consent was obtained from participants who agreed to take part in the study after declaration the aim of study. Their contact information was kept confidential.

Recruitment procedures:

Family physicians working in primary care in the city of Aydın were invited for participating in a trial. Twenty voluntary family physicians from 17 family health centers were included in the intervention arm of the trial.

All (smoking) patients who attended 17 family health centers from June 2023 to December 2023 were eligible for the trial.

Randomization (Participants):

The study was carried out in two phases. In the first phase, physicians who accepted to take part in the intervention group received one-hour online training on the intervention, in May 2023. Participant physicians were informed by study team about 3A-OR very brief smoking cessation advice that can be applied in 30-60 seconds. Additionally, a few documents that contain detailed information on intervention and brochures for distribution to smoking patients were shared with the physicians. Regardless of their previous practices, physicians were required to develop an approach to evaluating their patients' smoking habits in accordance with 3A-OR intervention. It was highlighted that 3A-OR very brief smoking cessation intervention was expected become a part of their daily routine clinical practices.

In second phase, data were collected between June-December 2023. In this period, a member of research team (YY) visited Family Health Centers of the physicians in the intervention arm, according to a pre-determined schedule. He invited smoking patients to participate in the study just after completing the consultation with their family physicians in waiting rooms of the health centers. Within the framework of the study protocol, patients of family physicians who had begun implementing 3A-OR very brief smoking cessation intervention as their routine clinical practices constituted the intervention group of the trial. Patients of the other family physicians in the same family health centers were assigned to the control group.

Before the study, power analysis was performed using one-way Fisher's Exact test in the Gpower software. In three-month follow up, with an anticipated abstinance rate of 15% in last 7 days in the intervention group (%5 in the control group) to create an effect size of %10, the sample size was calculated as 126 from each group and 252 in total. Based on the estimated number of smoking patients per single working day, it was aimed to include at least 10 smokers for each of 20 family physicians in the intervention group, targeting 200 smokers per group and 400 smokers in total. Eligible smokers were consecutively recruited without using any systematic or randomised sampling.

Intervention:

Physicians in the intervention arm applied the intervention of 3A-OR protocol that was developed by the research team. That protocol includes the stages of "Ask-Assess-Advice-Offer-Record". Further details of this intervention are provided in the Appendix.

The investigators assumed that physicians in the intervention group delivered very brief intervention about smoking cessation to all of their patients, but physicians in control group did not deliver such an intervention. Nevertheless, physicians in control group might have talked about smoking cessation with their patients as a part of their usual patient-physician relations.

Baseline and follow-up data collection:

Baseline data were collected by the same researcher in the waiting rooms of family health centers where the study was conducted. There was no follow-up contact during study period of three month for additional data collection. However, if participants revisited their doctors, that physician could repeat the intervention. Three months after first face-to-face interview, the follow-up data were collected via phone calls by the same researcher.

Participants who completed interview with their physicians of either group filled out data collection form together with the researcher, without knowing which group they appointed to. Participants were informed about study at minimal level with considering ethical concerns, so as unaware about current intervention. Participants who did not aware of their group situation were assigned according to the group of their family physician. Thus, participants were randomized to intervention or control group in accordance with their family physicians at baseline contact. In this respect, study was conducted in a single-blind design.

Study data were collected via questionnaire form which was developed for the purpose. The questionnaire consisted of 8 questions covering sociodemographic characteristics at first contact, 10 questions assessing smoking related characteristics and 11 questions determining their general health status. The level of nicotine addiction was determined using the short version of Fagerstrom Test for Nicotine Dependence (FTND).

Outcomes:

The trial had two main outcomes. Primarily, successful quitting defined as participants' abstinence from smoking for at least a week at the end of three months. Observed motivation change to quit of participant smokers was the secondary outcome.

Sociodemographic, medical and baseline smoking-related characteristics in the questionnaire were the independent variables of the trial.

Statistical analysis:

Statistical analyses were performed using SPSS 22.0 statistical software package. Descriptive analysis included percentages, means and standard deviations; the normality of data distribution was assessed with Kolmogorov-Smirnov test. For comparative assessment between groups, Pearson Chi-Square test, Fisher's Exact test, Cochran-Mantel-Haenszel test, Log-Linear test were conducted for categorical variables and Mann-Whitney U test, Kruskal-Wallis test, Wilcoxon test were applied for continuous variables. Binary Logistic Regression was performed to determine possible confounders. P values <0.05 was considered statistically significant.

Study design was guided by the PRECIS-2 (Pragmatic-Explanatory Continuum Indicator Summary) tool framework.

Being tested
Smoking cessation counselling group, Control group patients were those who had not received the 3A-OR intervention
Keywords
Smoking cessation, Primary health care, Pragmatic clinic trials, Randomized controlled trial, Motivation, Health behavior
Medical subject headings
Smoking Cessation, Tobacco Use Disorder, Health Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Smoking cessation counselling groupBehavioural

    3A-OR very brief intervention for smoking cessation

  • Control group patients were those who had not received the 3A-OR interventionBehavioural

    Control Group (Patients of the other family physicians in the same family health centers)

Study groups in NCT07030387
Study groupRoleWhat they receive
3A-OR very brief smoking cessation interventionExperimentalPatients of family physicians who had begun implementing 3A-OR very brief smoking cessation intervention as their routine clinical practices constituted the intervention group of the trial.
Receives: Behavioral: Smoking cessation counselling group
Control group: same-day patients of other family physicians in the same Family Health CentersExperimentalPatients of the other family physicians in the same family health centers were assigned to the control group.
Receives: Behavioral: Control group patients were those who had not received the 3A-OR intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Smoking Quit Rates

    Smoking cessation rates between groups at 3 months follow up

    Measured: 3 months after the 3A-OR very brief intervention

Secondary outcomes (1)
  1. Motivational stages of quitting smoking

    Smokers' motivational stage of quit smoking assessment with Prochaska's Transtheoretical Model (Stages of Change: Pre-contemplation, Contemplation, Preparation, Action, and Maintenance) in both the intervention and control groups at baseline and at the 3-month follow-up.

    Measured: 3 months after the 3A-OR very brief intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2025
  2. Study start1 Jun 2023
  3. Primary completion31 Dec 2023
  4. Study completion31 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
3A-OR Model (Ask - Assess - Advise - Offer Assistance - Record) In this brief intervention algorithm, the physician primarily learns every patient's smoking status, assesses the smoker's motivation to quit, advises cessation with different approaches for the pre-contemplation and contemplation/preparation stages, then offers assistance, and finally records the encounter in the patient's file. 1. (A) LEARN! 2. (A) ASSESS! If the smoker is in the PRE-CONTEMPLATION stage: 3. (A) ADVISE! 4. (O) OFFER ASSISTANCE! 5. (R) RECORD! If the smoker is in the CONTEMPLATION or PREPARATION stage: 3\. (A) ADVISE! 4. (O) OFFER ASSISTANCE! 5. (R) RECORD!
Masking
Single blind
Who is masked
Participant
Enrolment
330 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07030387
Sponsor's protocol ID
2022/217
Status last verified
Jun 2025
First submitted
5 Jun 2025
Last updated
22 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Russell MA, Wilson C, Taylor C, Baker CD. Effect of general practitioners' advice against smoking. Br Med J. 1979 Jul 28;2(6184):231-5. doi: 10.1136/bmj.2.6184.231.

    PubMed 476401
  • Jamrozik K, Vessey M, Fowler G, Wald N, Parker G, Van Vunakis H. Controlled trial of three different antismoking interventions in general practice. Br Med J (Clin Res Ed). 1984 May 19;288(6429):1499-503. doi: 10.1136/bmj.288.6429.1499.

    PubMed 6426618
  • Yilmaz G, Karacan C, Yoney A, Yilmaz T. Brief intervention on maternal smoking: a randomized controlled trial. Child Care Health Dev. 2006 Jan;32(1):73-9. doi: 10.1111/j.1365-2214.2006.00570.x.

    PubMed 16398793
  • Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015 May 8;350:h2147. doi: 10.1136/bmj.h2147. No abstract available.

    PubMed 25956159
  • Wu L, He Y, Jiang B, Zhang D, Tian H, Zuo F, Lam TH. Very brief physician advice and supplemental proactive telephone calls to promote smoking reduction and cessation in Chinese male smokers with no intention to quit: a randomized trial. Addiction. 2017 Nov;112(11):2032-2040. doi: 10.1111/add.13908. Epub 2017 Aug 2.

    PubMed 28623848
  • Lin PR, Zhao ZW, Cheng KK, Lam TH. The effect of physician's 30 s smoking cessation intervention for male medical outpatients: a pilot randomized controlled trial. J Public Health (Oxf). 2013 Sep;35(3):375-83. doi: 10.1093/pubmed/fdt018. Epub 2013 Mar 13.

    PubMed 23487178
  • Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008 Aug;35(2):158-76. doi: 10.1016/j.amepre.2008.04.009.

    PubMed 18617085
  • Bobak A, Raupach T. Effect of a Short Smoking Cessation Training Session on Smoking Cessation Behavior and Its Determinants Among General Practitioner Trainees in England. Nicotine Tob Res. 2018 Nov 15;20(12):1525-1528. doi: 10.1093/ntr/ntx241.

    PubMed 29099979
  • Cheung YTD, Jiang N, Jiang CQ, Zhuang RS, Gao WH, Zhou J, Lu JH, Li H, Wang JF, Lai YS, Sun JS, Wu JC, Ye C, Li N, Zhou G, Chen JY, Ou XY, Liu LQ, Huang ZH, Ho SY, Li HCW, Su SH, Yang Y, Jiang Y, Zhu WH, Yang L, Lin P, He Y, Cheng KK, Lam TH. Physicians' very brief (30-sec) intervention for smoking cessation on 13 671 smokers in China: a pragmatic randomized controlled trial. Addiction. 2021 May;116(5):1172-1185. doi: 10.1111/add.15262. Epub 2020 Oct 5.

    PubMed 32918512
  • Wray JM, Funderburk JS, Acker JD, Wray LO, Maisto SA. A Meta-Analysis of Brief Tobacco Interventions for Use in Integrated Primary Care. Nicotine Tob Res. 2018 Nov 15;20(12):1418-1426. doi: 10.1093/ntr/ntx212.

    PubMed 29059419
  • West R, Raw M, McNeill A, Stead L, Aveyard P, Bitton J, Stapleton J, McRobbie H, Pokhrel S, Lester-George A, Borland R. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015 Sep;110(9):1388-403. doi: 10.1111/add.12998.

    PubMed 26031929
  • Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD000165. doi: 10.1002/14651858.CD000165.pub4.

    PubMed 23728631
  • Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012 Jun;107(6):1066-73. doi: 10.1111/j.1360-0443.2011.03770.x. Epub 2012 Feb 28.

    PubMed 22175545
  • Wang L, Jin Y, Lu B, Ferketich AK. A Cross-Country Study of Smoking Cessation Assistance Utilization in 16 Low and Middle Income Countries: Data From the Global Adult Tobacco Survey (2008-2012). Nicotine Tob Res. 2016 May;18(5):1076-82. doi: 10.1093/ntr/ntv139. Epub 2015 Jun 25.

    PubMed 26116084
  • Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004 Jun 26;328(7455):1519. doi: 10.1136/bmj.38142.554479.AE. Epub 2004 Jun 22.

    PubMed 15213107

Questions about this trial

What is this clinical trial studying?

A study testing Smoking cessation counselling group in people with Smoking Cessation; Tobacco Dependence, run by Aydin Adnan Menderes University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Smoking Quit Rates (time frame: 3 months after the 3A-OR very brief intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07030387, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in